evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract
19235,GENE_SUMMARY,,"MEF2B encodes a transcriptional activator that is involved in muscle-specific gene expression. Mutations of MEF2B are found in diffuse large B cell lymphomas and follicular lymphomas, among other cancers.",,2017-03-10,,100271849,MEF2B,myocyte enhancer factor 2B,True,ENST00000162023,NM_001145785.1,RSRFR2,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19236,GENE_BACKGROUND,,"MEF2B encodes a transcription factor of the myocyte enhancer factor 2 (MEF2) family of human transcription factors. The family consists of four proteins, MEF2A, -B, -C and -D, all of which contain three domains: an N-terminal DNA-binding MADS domain, a central MEF2 domain and a C-terminal transactivation domain (PMID: 17959722). MEF2B mediates de-differentiation of vascular smooth muscle cells in response to cyclic stretch. In HEK293 cells, MEF2B target genes were enriched for regulators of cell migration, genes involved in the epithelial-mesenchymal transition as well as the cancer genes MYC, TGFB1, CARD11, RHOB and NDRG1 (PMID: 22955990). MEF2B, has been found amplified in 3 to 9% of ovarian serous cystadenocarcinomas, adrenocortical carcinomas and esophageal carcinomas (PMID: 26506234), indicating that it may have oncogenic activity. Indeed, MEF2B promoted a mesenchymal gene expression signature and increased cell migration when overexpressed in HEK293 cells (PMID: 26245647). MEF2B is the target of heterozygous somatic non-synonymous and indel mutations in 8 to 18% of diffuse large B-cell lymphoma (DLBCL) (PMID: 21796119, 22343534, 21804550, 23292937), 13% of follicular lymphoma (FL) (PMID: 21796119) and 3 to 7% of mantle cell lymphoma (MCL) (PMID: 24145436). Other MEF2 proteins were much less commonly affected in lymphoma (PMID: 21796119, 22343534), indicating that MEF2B has a role unique from its paralogs in the B-cells from which these lymphomas arise. Mutations in the MADS and MEF2 domains represented 79% of MEF2B mutations in DLBCL (PMID: 21796119, 22343534, 21804550, 23292937), 75% of MEF2B mutations in FL (PMID: 21796119) and 93% of MEF2B mutations in MCL (PMID: 24145436). Mutation hotspots in DLBCL and FL were present at K4 (7% of mutations), Y69 (8% of mutations) and D83 (33% of mutations) (PMID:21796119, 21804550, 23292937). In contrast, MEF2B mutations in MCL were predominantly K23R mutations (10 out of 14 mutations) (PMID:24145436). It is unknown why the mutation spectrum differs between MCL and other lymphomas. The recurrence of MEF2B mutations at particular residues is consistent with the notion that MEF2B mutations have either gain-of-function or dominant negative effects on MEF2B activity. Preliminary data indicates that loss of MEF2B activity de-represses DLBCL cell chemotaxis, indicating that the mutations may contribute to DLBCL and FL development by allowing migration outside of germinal centers (PMID: 26245647). MEF2B mutations also increased expression of the MYC oncogene and decreased expression of the TGFB1 tumor suppressor in HEK293 cells (PMID:26245647). Such expression changes in DLBCL would be expected to promote lymphoma development (PMID: 24009228, 26506234)",,2017-03-10,,100271849,MEF2B,myocyte enhancer factor 2B,True,ENST00000162023,NM_001145785.1,RSRFR2,False,21804550,Analysis of the coding genome of diffuse large B-cell lymphoma.,Nature genetics,2018-07-31T20:11:00,43,9,830-7,Pasqualucci L et al,doi: 10.1038/ng.892,,0001-07-31,,24009228,Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.,Blood,2017-12-05T20:13:00,122,24,3884-91,Ott G et al,doi: 10.1182/blood-2013-05-498329,,0001-12-05,,22955990,Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors.,Genome research,2018-09-01T20:12:00,22,9,1798-812,Wang J et al,doi: 10.1101/gr.139105.112,,2018-09-01T08:12:00,,22343534,Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.,Proceedings of the National Academy of Sciences of the United States of America,2018-03-06T20:12:00,109,10,3879-84,Lohr JG et al,doi: 10.1073/pnas.1121343109,,0001-03-06,,26506234,MEF2 transcription factors: developmental regulators and emerging cancer genes.,Oncotarget,2018-01-19T20:16:00,7,3,2297-312,Pon JR et al,doi: 10.18632/oncotarget.6223,,2018-01-19T03:12:00,,21796119,Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.,Nature,2018-07-27T20:11:00,476,7360,298-303,Morin RD et al,doi: 10.1038/nature10351,,2018-07-27T03:03:00,,26245647,MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.,Nature communications,2018-08-06T20:15:00,6,,7953,Pon JR et al,doi: 10.1038/ncomms8953,,0001-08-06,,23292937,Genetic heterogeneity of diffuse large B-cell lymphoma.,Proceedings of the National Academy of Sciences of the United States of America,2018-01-22T20:13:00,110,4,1398-403,Zhang J et al,doi: 10.1073/pnas.1205299110,,2018-01-22T04:03:00,,24145436,Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.,Proceedings of the National Academy of Sciences of the United States of America,2018-11-05T20:13:00,110,45,18250-5,Be√† S et al,doi: 10.1073/pnas.1314608110,,0001-11-05,,17959722,MEF2: a central regulator of diverse developmental programs.,"Development (Cambridge, England)",2017-12-01T20:07:00,134,23,4131-40,Potthoff MJ et al,,,0001-12-01,
